Eko Foundation Analysis Software with Transformers (EFAST) vs EchoNext

EFAST integrates seamlessly with Eko's digital stethoscopes, providing real-time AI analysis, enhanced audio, waveform visualization, and guided exams directly at the point of care. This direct integration into a physical device and existing workflow likely offers a more immediate and intuitive user experience compared to EchoNext, which is deployed through a separate clinical decision support platform.

While both tools are FDA-cleared and offer strong diagnostic capabilities, EchoNext's ability to detect a broader range of hidden structural heart diseases from a standard ECG, including heart failure, valve disease, and pulmonary hypertension, gives it a slight edge. EchoNext has also demonstrated higher accuracy in identifying structural heart problems compared to cardiologists, even those with AI assistance.

EFAST uses a subscription-based model with a free trial included with stethoscope purchase, and the stethoscope technology costs around $2.00/day. EchoNext starts at $600/month with tiered pricing and an implementation fee for most plans. Without more detailed information on EFAST's subscription costs and how the overall cost of ownership compares for various practice sizes, it's difficult to definitively declare a winner in terms of pricing and value. Both offer annual discounts.

EchoNext is available through the OpenEvidence clinical decision support platform, which is used by a large number of U.S. physicians, suggesting a wider existing integration and easier deployment within various healthcare systems. Pathway Labs has also secured significant seed funding to support expansion across health systems.

EchoNext is highlighted as the world's first FDA-approved AI detection tool that analyzes ECGs to detect high-risk structural heart disease, and the first FDA-cleared AI platform to identify multiple high-risk cardiac conditions from standard ECGs. This pioneering approach to using a widely available and inexpensive test (ECG) for broad structural heart disease screening represents a significant innovation in early detection.

Both companies are FDA-cleared and HIPAA compliant, indicating a commitment to regulatory standards and data security. While Eko Health provides a help center with regulatory information and details on their algorithms, specific details about the breadth and accessibility of support and documentation for both tools are not extensively detailed in the provided information or web searches, leading to a tie.